Merck ’s V116, an Investigational, 21-valent Pneumococcal Conjugate Vaccine Specifically Designed to Protect Adults, Demonstrated Superior Immunogenicity for 10 of 11 Unique Serotypes Compared to PCV20 in Adults 50 Years of Age and Older

The 21 serotypes covered by V116 are responsible for approximately 83% of invasive pneumococcal disease in individuals 65 years of age and older, according to CDC data from 2018-2021 Results from Phase 3 trial, STRIDE-3, to be presented at World...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials